COVID-19 Death and BCG Vaccination Programs Worldwide
Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p<0.001, MannWhitney test). Therefore, it can be concluded that the early establishment of a BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
Tuberculosis and respiratory diseases - 84(2021), 1 vom: 25. Jan., Seite 13-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jirjees, Feras J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BCG Vaccine |
|---|
| Anmerkungen: |
Date Revised 22.01.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4046/trd.2020.0063 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314559280 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314559280 | ||
| 003 | DE-627 | ||
| 005 | 20231225153005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4046/trd.2020.0063 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314559280 | ||
| 035 | |a (NLM)32883062 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jirjees, Feras J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Death and BCG Vaccination Programs Worldwide |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p<0.001, MannWhitney test). Therefore, it can be concluded that the early establishment of a BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BCG Vaccine | |
| 650 | 4 | |a COVID-19 Death Cases | |
| 650 | 4 | |a COVID-19 Mortality | |
| 650 | 4 | |a COVID-19 Pandemic | |
| 650 | 4 | |a Coronavirus | |
| 700 | 1 | |a Dallal Bashi, Yahya H |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Obaidi, Hala J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tuberculosis and respiratory diseases |d 2012 |g 84(2021), 1 vom: 25. Jan., Seite 13-21 |w (DE-627)NLM222134194 |x 1738-3536 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2021 |g number:1 |g day:25 |g month:01 |g pages:13-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4046/trd.2020.0063 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2021 |e 1 |b 25 |c 01 |h 13-21 | ||